Vilya
Seattle, Washington, United States
Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology. The Company’s proprietary platform, powered by advanced machine learning and generative AI, taps into uncharted chemical space to design de novo molecular structures with enhanced drug-like properties that range in size between small molecules and antibodies. Vilya is leveraging its platform to focus on previously difficult-to-drug therapeutic targets. Vilya was co-founded by a team of scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., and ARCH Venture Partners.
Company Info
- Founded
- 2022
- Website
- vilyatx.com/
Only accessible to MedStartr community members.
Join nowWhat do you think of Vilya?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.